Luye Pharma Subsidiary Issues Exchangeable Preference Shares to Bluebell Asset Holding

Reuters12-12 22:30
<a href="https://laohu8.com/S/LYPHF">Luye Pharma</a> Subsidiary Issues Exchangeable Preference Shares to Bluebell Asset Holding

Luye Pharma Group Ltd. announced the completion of a discloseable transaction involving the issue of 1,500,000 exchangeable preference shares by its wholly-owned subsidiary, Luye Geneora Holding Limited. The shares were subscribed by Bluebell Asset Holding Ltd., an investment holding company focused on the healthcare sector in Asia and ultimately owned by RRJ Capital. The proceeds from this transaction will be used for the group's general working capital purposes, including payments to suppliers, employee salaries, directors' remuneration, and other management and administrative expenses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luye Pharma Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251212-11954685), on December 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment